Q-omics provides the consensus-scored GLUD1P3 profile across patient tissues and cancer cell-line models. GLUD1P3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GLUD1P3 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, GLUD1P3 RNA expression shows 20,317 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where GLUD1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLUD1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLUD1P3 survival associations across molecular data types. GLUD1P3 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLUD1P3 RNA expression–survival associations across cancer types. High GLUD1P3 expression shows unfavorable associations in KIRC, ACC and COAD, but favorable associations in HNSC, UCS and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for GLUD1P3 RNA expression.
This table summarizes GLUD1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GLUD1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLUD1P3 shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in LIHC, CHOL and PRAD. The LIHC box plot shows higher GLUD1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.839, t-test p < 0.001).
This table shows molecular features associated with GLUD1P3 in patient tissues and cancer cell lines. In patient samples, GLUD1P3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
